Table 5 Radiologic response at completion of chemoradiotherapy (RECIST version 1.0)

From: Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer

 

Dose levels

 

Response parameters

1 ( n =6)

2 ( n =6)

3 ( n =3)

4 ( n =3)

5 ( n =3)

6 ( n =3)

No. (%) (Total n =24)

Overall best response

 Complete response

4

1

0

2

1

0

8 (33)

 Partial response

1

3

0

0

0

0

4 (17)

 Stable disease

0

0

3

0

1

1

5 (21)

 Progressive disease

1

2

0

0

1

1

5 (21)

 Not evaluablea

0

0

0

1

0

1

2 (8)

Best response in radiotherapy field

 Complete response

4

2

0

2

1

0

9 (37)

 Partial response

1

3

0

0

0

0

4 (17)

 Stable disease

0

0

3

0

1

1

5 (21)

 Progressive disease

1

1

0

0

0

1

3 (13)

 Not evaluableb

0

0

0

1

1

1

3 (13)

  1. aOne patient not evaluable by radiologic criteria (DL6), one patient lost to follow-up (DL4).
  2. bPatient in DL5 not evaluable at primary site, progressive disease systemically.